Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant lines.

This study establishes YAP1/TAZ-TEAD signaling as a shared oncogenic dependency in meningioma and demonstrates that while TEAD inhibition alone shows variable efficacy, combining it with MEK or mTOR inhibitors effectively overcomes resistance in NF2 wild-type and higher-grade tumors by targeting compensatory signaling pathways.

The Gist

The Big Picture: The "Stuck Accelerator" Problem

Imagine the human body is a city, and the cells are the cars driving on the streets. Usually, there are traffic lights and brakes (like the NF2 gene) that tell the cars when to stop or slow down.

In a common type of brain tumor called a meningioma, the traffic lights are broken. Specifically, the "brake" gene called NF2 is missing or broken in many of these tumors. Without brakes, the cars (cells) start speeding up and multiplying uncontrollably.

For a long time, doctors have tried to stop these tumors with surgery, radiation, or standard chemotherapy (like trying to stop a speeding car by throwing a net over it). But often, the tumors come back, or they are in places too dangerous to operate on. We need a better way to hit the brakes.

The Discovery: Finding the "Engine"

The researchers in this study found that when the brakes (NF2) break, a specific engine part called YAP1/TAZ gets stuck in the "ON" position. This engine talks to a control panel called TEAD. Together, they scream at the cells: "Grow! Grow! Grow!"

The team asked: What if we could turn off this engine?

They tested two things:

1. Genetic Surgery: They used a molecular "scissors" (CRISPR) to cut out the YAP1/TAZ engine parts.
   • Result: In almost all the tumor cells, the cars stopped moving. The tumors couldn't grow. This proved that this engine is essential for the tumor's survival.
2. Chemical Brakes (TEAD Inhibitors): They tried four different drugs designed to jam the TEAD control panel, stopping the engine from working.

The Twist: The "Escape Routes"

Here is where it gets tricky.

• The Easy Wins: In "low-grade" (slower-growing) tumors, the chemical brakes worked perfectly. The tumors shrank or stopped growing.
• The Hard Mode: In "high-grade" (aggressive) tumors and some others, the drugs didn't work as well. The tumors kept growing, even with the brakes applied.

Why?
The researchers discovered that these tough tumors are like clever escape artists. When you jam the TEAD control panel, the tumor cells panic and immediately open up backup escape routes. They activate two other "highways" to keep the engine running:

1. The MEK Highway: A fast lane for growth.
2. The mTOR Highway: A super-highway for energy and building new cells.

It's like trying to stop a car by blocking the front door, but the driver just jumps out the back window and keeps running.

The Solution: The "Double-Team" Strategy

The researchers realized that to stop these tough tumors, you can't just block the front door (TEAD). You have to block the front door AND the back window at the same time.

They tested a new strategy: Combination Therapy.

• Drug A: Blocks the TEAD engine (the main problem).
• Drug B: Blocks the MEK or mTOR escape routes (the backup plan).

The Result:
When they used both drugs together, the tough tumors finally stopped.

• Using Drug A alone? The tumor fought back.
• Using Drug B alone? The tumor ignored it.
• Using both together? The tumor was completely overwhelmed. The combination was much stronger than either drug alone.

They also found that drugs already approved by the FDA (like Everolimus, usually used for kidney cancer) could work as the "Drug B" in this team-up, making this a very realistic option for future treatments.

The Takeaway

This study is like a detective story where the investigators found the main culprit (the TEAD engine) but realized the criminal had a plan B (the escape routes).

1. TEAD inhibitors are a promising new way to treat meningiomas, especially the slower-growing ones.
2. For the aggressive, resistant tumors, we need to combine drugs. By hitting the main engine and the backup escape routes simultaneously, we can stop the tumor from growing.
3. This gives hope that in the future, patients with hard-to-treat meningiomas might have effective, targeted pills to take, rather than just surgery or radiation.

In short: We found the tumor's weak spot, but the tumor tried to hide. By using a "two-pronged attack," we can finally catch it.

Technical Summary

1. Problem Statement

Meningiomas are the most common primary central nervous system (CNS) tumors in adults. While low-grade meningiomas are often curable via surgery or radiation, high-grade tumors and those located in surgically inaccessible areas (e.g., skull base, optic nerve sheath) frequently recur and are fatal. Current systemic therapies (chemotherapy) are largely ineffective, and no targeted treatments are FDA-approved.

• Molecular Context: A significant subset of meningiomas (40–60%) involves NF2 loss, which dysregulates the Hippo signaling pathway, leading to the nuclear accumulation of transcriptional co-activators YAP1 and TAZ. These bind to TEAD transcription factors to drive oncogenic proliferation. Additionally, NF2-wild-type tumors may harbor YAP1 fusions that constitutively activate this pathway.
• The Gap: While TEAD inhibitors (TEADi) are in clinical trials for other NF2-deficient tumors, their efficacy in meningioma is unproven. Crucially, the mechanisms of resistance to TEAD inhibition in meningioma and potential strategies to overcome them (e.g., combination therapies) have not been systematically investigated.

2. Methodology

The study utilized a multi-faceted approach combining genetic, pharmacological, and transcriptomic analyses:

• Cell Models: A panel of 21 human meningioma cell lines was used, including 4 established lines (e.g., BenMen1, CH-157MN, IOMM-Lee) and 17 primary patient-derived lines. These were stratified by NF2 status (mutant vs. wild-type) and tumor grade (low vs. high).
• Genetic Ablation: CRISPR-Cas9 was used to generate double-knockout (DKO) lines for YAP1 and TAZ to assess the necessity of this axis for cell growth.
• Pharmacological Screening: Four distinct TEAD inhibitors (IAG-933, MYF-03-176, GNE-7883, K-975) were tested across the cell panel using live-cell imaging and CellTiter-Glo viability assays to determine IC50 values and classify lines as "sensitive" or "resistant."
• Omics Analysis:
  • RNA-Seq: Performed on sensitive and resistant lines treated with TEADi vs. DMSO to identify transcriptional changes and compensatory pathways.
  • Western Blotting: Analyzed phosphorylation levels of key signaling nodes (AKT, S6, ERK) to validate pathway activation states.
• Combination Therapy: Resistant lines were treated with TEADi in combination with MEK inhibitors (trametinib), mTOR inhibitors (torin-2, everolimus, rapamycin, sapanisertib), PI3K inhibitors (pictilisib), or FAK inhibitors (TAE226). Synergy was quantified using SynergyFinder 3.0.

3. Key Contributions

1. Validation of Shared Oncogenic Dependency: Demonstrated that YAP1/TAZ-TEAD signaling is a critical driver in both NF2-mutant and NF2-wild-type meningiomas, as genetic ablation of both YAP1 and TAZ significantly suppressed growth across all subtypes.
2. Identification of Resistance Mechanisms: Uncovered that while TEADi effectively downregulates YAP1/TAZ target genes in resistant lines, these cells survive by activating compensatory MEK-ERK and mTOR-S6 signaling pathways. Notably, this activation occurs independently of the PI3K-AKT axis.
3. Therapeutic Strategy for Resistance: Established that co-targeting the compensatory pathways (MEK or mTOR) with TEADi overcomes resistance, yielding superior efficacy compared to single agents or dual inhibition of MEK/mTOR without TEADi.
4. Translational Relevance: Validated that FDA-approved mTOR inhibitors (everolimus, rapamycin, sapanisertib) can effectively replace experimental mTOR inhibitors (torin-2) in combination regimens, facilitating immediate clinical translation.

4. Key Results

• Genetic Dependency: YAP1/TAZ double knockout caused near-complete growth arrest in low-grade NF2-mutant lines and significant growth reduction in high-grade NF2-mutant and NF2-wild-type lines.
• TEAD Inhibitor Efficacy:
  • Sensitivity: Low-grade NF2-mutant lines were generally sensitive to TEADi (IC50 < 250 nM for IAG-933).
  • Resistance: High-grade NF2-mutant lines showed mixed sensitivity, while NF2-wild-type lines were generally resistant (IC50 often > 1500 nM).
  • Mechanism of Resistance: Resistant lines still showed downregulation of YAP1/TAZ target genes (e.g., CTGF, CYR61) upon treatment, indicating the drug was on-target. However, RNA-Seq and Western blots revealed a paradoxical upregulation of p-ERK and p-S6 (mTOR pathway) in resistant lines, but not sensitive ones.
• Combination Therapy Success:
  • MEK/mTOR Synergy: Combining TEADi (IAG-933) with MEKi (trametinib) or mTORi (torin-2) restored sensitivity in resistant lines. Synergy was observed at very low concentrations (1 nM).
  • Superiority: The triple-target approach (TEAD + MEK/mTOR) was more effective than MEK/mTOR inhibition alone.
  • FDA-Approved Agents: Everolimus, rapamycin, and sapanisertib showed similar efficacy to torin-2 when combined with TEADi in resistant lines.
  • FAK Inhibition: FAK inhibition (TAE226) showed additive effects in a subset of lines but was less potent than MEK/mTOR combinations.
• PI3K-AKT Independence: Phospho-AKT levels decreased or remained unchanged upon TEADi treatment, suggesting the compensatory mTOR-S6 activation in resistant cells is driven via ERK (potentially through RSK or TSC2 inhibition) rather than PI3K-AKT.

5. Significance and Future Directions

• Proof of Concept: This study provides the first comprehensive evidence that TEAD inhibition is a viable therapeutic strategy for meningioma, particularly for NF2-mutant subtypes.
• Overcoming Clinical Hurdles: The identification of adaptive resistance mechanisms (MEK/mTOR upregulation) offers a clear rationale for combination therapy, which is likely necessary for clinical success given the emergence of resistance in monotherapy trials for other cancers.
• Clinical Translation: The finding that FDA-approved mTOR inhibitors can synergize with TEADi suggests that clinical trials could be designed using existing drugs, potentially accelerating the path to treatment for high-grade and recurrent meningiomas.
• Limitations & Next Steps: The study is limited to short-term in vitro models. Future work must address long-term resistance mechanisms (e.g., AP-1, MYC upregulation), potential on-target toxicities of TEADi (e.g., kidney toxicity), and in vivo validation of these combination regimens.

In summary, the paper establishes YAP1/TAZ-TEAD as a central oncogenic driver in meningioma and proposes a robust, mechanistically grounded combination therapy (TEADi + MEK/mTORi) to treat resistant and high-grade disease.